Company intelligence / Profile preview

Atvio Biotech

Nesher, Haifa District, Israel

Ownership: Private
Development stage: Other

Overview

Atvio Biotech is an Israeli contract development and manufacturing organization (CDMO) specializing in cGMP cell and gene therapy manufacturing, process development, custom automation, virus manufacturing, and the translation of cell therapies from lab to market. It is known for its process innovation and was acquired by Orgenesis in 2018, becoming part of Orgenesis’ global CDMO network. There is no public evidence of Atvio having its own proprietary therapeutic pipeline; its role is primarily as a manufacturing and process development partner for biotech and pharma companies.[1][3]

Modalities: Cell therapyGene therapy
Industry: Contract Manufacturing Organization

Partnerships

OrgenesisLonza

Beyond the preview

Go deeper on Atvio Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atvio Biotech.

Explore the full profile